Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases

NCT03277313 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT03277313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03277313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
September 25, 2017
Completion date
July 20, 2022
Enrollment
44 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency diseases (pid)